
|Articles|March 14, 2014
Euro Medicines Agency Updates List of Tenders
On March 13, the European Medicines Agency published updated information about current tenders...
Advertisement
On March 13, the European Medicines Agency (EMA) published updated information about current tenders—documents that explain a project and its requirements to intending bidders—worth more than £60,000 ($99,700).
The newest tender to be unveiled consists of a contract worth 1.2 million euros for the provision of information resources at the Agency itself. The closing date is June 4, 2014.
Further details about the latest tenders—which typically contain a notice inviting tenders, instructions to bidders, the conditions, form of submission, and bill of quantities—are available via this link:
Advertisement
Related to this article

In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.

IgniteData and RealTime Partner to Streamline Clinical Data Transfer From eSource to Sponsor Systems
The partnership gives RealTime's network of more than 3,000 research sites access to the Archer platform for direct, automated data transfer from eSource to any sponsor electronic data capture system or data destination.

In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, identify three persistent obstacles to consistent real-world evidence generation in oncology—inconsistent data capture, structural data limitations that modeling alone can't fix, and the need for earned generalizability through deliberate multi-site validation.

How a phased CRO partnership built on ICH E6(R2) and E6(R3) principles supported a multi-indication biotech portfolio.

The second of a two-part perspective examining why clinical trial enrollment and representation outcomes are shaped long before the first patient is screened.

In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, describe what operationalizing regulatory-grade quality frameworks requires—and why fit-for-purpose evidence generation is a transparency and documentation discipline, not just a data cleanliness exercise.

AI can turn complex protocols into first-pass budget inputs, letting sponsors start budgeting sooner while budget builders shift from data entry to review.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
IgniteData and RealTime Partner to Streamline Clinical Data Transfer From eSource to Sponsor Systems
2
The Biggest Remaining Barriers to High-Quality RWE Across Oncology Data Platforms
3
Beyond Outreach: Structural Drivers of Representation in Clinical Trials
4
Flexible Clinical Operations and Site Management Across a Diversified Biotech Portfolio: An Application of Quality by Design and Risk-Based Oversight
5

